| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/22/1995 | EP0643576A1 Alpha-2-adrenergic agonists for treating presbyopia |
| 03/21/1995 | US5399586 Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity |
| 03/21/1995 | US5399581 Administering mixture of nonselective alpha 1-alpha 2, and beta adrenergic blocking agents having vasodilator activity |
| 03/21/1995 | US5399363 IV administration for insoluble medicaments |
| 03/16/1995 | WO1995007103A1 Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive |
| 03/16/1995 | WO1995007100A1 Compounds for the prevention and treatment of helminth infections |
| 03/16/1995 | WO1995007098A1 Methods for regulating gastrointestinal motility |
| 03/16/1995 | WO1995007091A1 Uses of vegetable oils |
| 03/16/1995 | WO1995007089A1 Immunomodulating compositions from bile |
| 03/16/1995 | WO1995007080A1 A method of treating liver disease and like indications with vasodilating agents |
| 03/16/1995 | WO1995007079A1 Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agents and caffeine |
| 03/16/1995 | WO1995007075A1 Novel aromatic amine derivatives |
| 03/16/1995 | WO1995007023A1 Method and composition for the treatment of apathy-amotivation syndrome |
| 03/16/1995 | WO1995002420A3 Prodrugs of protein tyrosine kinase inhibitors |
| 03/16/1995 | CA2171198A1 Method and composition for the treatment of apathy-amotivation syndrome |
| 03/16/1995 | CA2170488A1 Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive |
| 03/15/1995 | EP0642797A1 Formulation comprising antibacterial substance and antiulcer substance |
| 03/15/1995 | EP0642787A2 Cessation of tobacco use |
| 03/15/1995 | EP0642784A1 Effervescent mixture containing the alkaline salts or lysinates of insoluble or hardly soluble acid drugs |
| 03/15/1995 | EP0642591A1 Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| 03/15/1995 | EP0642340A1 Compositions based on histamine h 2?-receptor antagonists and cationic exchangers complexes |
| 03/15/1995 | EP0642336A1 Use of nsiad in the treatment of dementia |
| 03/15/1995 | EP0433393B1 Treatment of damaged bone marrow and dosage units therefor |
| 03/15/1995 | EP0414741B1 Further improvements relating to drug delivery systems |
| 03/14/1995 | US5397797 Treatment of ocular hypertension with an ocular synergistic combination |
| 03/14/1995 | US5397791 Fibrinogen receptor antagonists |
| 03/14/1995 | US5397786 Rehydration drink |
| 03/14/1995 | US5397703 Method for generation of antibodies to cell surface molecules |
| 03/14/1995 | CA2029047C Sustained release compositions for treating periodontal disease |
| 03/10/1995 | CA2131569A1 Formulation comprising antibacterial substance and antiulcer substance |
| 03/10/1995 | CA2131487A1 Cessation of tobacco use |
| 03/09/1995 | WO1995006480A1 Methods of prolonged suppression of humoral immunity |
| 03/09/1995 | WO1995006467A1 Treatment of laminitis |
| 03/09/1995 | WO1995006466A1 Treatment of anorectal disorders |
| 03/09/1995 | WO1995006410A1 Treatment of chronic inflammatory diseases by angiotension ii receptor antagonists |
| 03/09/1995 | CA2131512A1 Nutritional supplement |
| 03/08/1995 | EP0641562A1 Nutritional supplement |
| 03/08/1995 | EP0641557A1 Dermatologic or cosmetic composition made up by an oil in water emulsion based on oily globules coated with a lamellar liquid crystall coating |
| 03/08/1995 | EP0641359A1 Methods and compositions for the treatment of diseases with interferon while reducing side effects |
| 03/08/1995 | EP0641353A1 Anti-sense oligonucleotides for isotype-specific suppression of immunoglobulin production |
| 03/08/1995 | EP0641221A1 Anhydrous formulations for administering lipophilic agents |
| 03/08/1995 | EP0641218A1 Use of renin-angiotensin antagonist for reducing post myocardial infarct mobidity and mortality |
| 03/08/1995 | EP0641202A1 Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease |
| 03/08/1995 | EP0641198A1 Medicaments for the treatment of anxiety |
| 03/08/1995 | EP0641193A1 Chemotherapeutic drug combinations |
| 03/08/1995 | EP0466769B1 Reducing post-prandial plasma large neutral amino acid concentrations |
| 03/07/1995 | CA1334649C Chemical splinter removal |
| 03/07/1995 | CA1334646C Transdermal penetration enhancers |
| 03/02/1995 | WO1995006077A2 Polymeric matrices and their uses in pharmaceutical compositions |
| 03/02/1995 | WO1995005852A1 Agent against sensitive, hyperreactive and hypoactive states of the skin, forms of acne, atopic dermatitides, psoriasis, prurigo, photodermatoses, ichthyosis and viral infections |
| 03/02/1995 | WO1995005833A1 Pharmaceutical composition for immunoenhancement therapy |
| 03/02/1995 | WO1995005832A1 Heart function restorative |
| 03/02/1995 | WO1995005828A1 Progesterone-antagonistic and anti-oestrogen compounds for the therapy of leiomyomata uteri |
| 03/02/1995 | WO1995005819A1 Methods for treating circadian rhythm phase disturbances |
| 03/02/1995 | WO1995005810A1 Compositions and methods for the detection and treatment of protein trafficking disorders and increasing secretory protein production |
| 03/02/1995 | WO1994028726A3 Method of treating retained pulmonary secretions |
| 03/02/1995 | CA2169210A1 Compositions and methods for the detection and treatment of protein trafficking disorders and increasing secretory protein production |
| 03/02/1995 | CA2146242A1 Heart function restorative |
| 03/01/1995 | EP0640352A1 Preparation of a skin surface for a surgical procedure |
| 03/01/1995 | EP0640345A2 Composition for inhibiting transmission of AIDS, containing silver salts with a detergent |
| 03/01/1995 | EP0639986A1 Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents |
| 03/01/1995 | EP0639973A1 Diamines in the treatment of arrhythmia |
| 03/01/1995 | EP0639970A1 Contraception method using competitive progesterone antagonists and novel compounds useful therein |
| 03/01/1995 | EP0390911B1 Low-melting moldable pharmaceutical excipient and its use with pharmaceutical compositions |
| 02/28/1995 | US5393883 Ribonucleotide reductase inhibitors |
| 02/28/1995 | CA2130015A1 Preparation of a skin surface for a surgical procedure |
| 02/26/1995 | CA2130025A1 Method of treating fungal infections |
| 02/23/1995 | WO1995005456A1 Pharmaceutical composition comprising phosphatase or a derivative thereof |
| 02/23/1995 | WO1995005455A1 Pharmaceutical composition comprising phosphatase or a derivative thereof |
| 02/23/1995 | WO1995005397A1 Composition and methods using nitroxides to avoid oxygen toxicity |
| 02/23/1995 | WO1995005188A1 Erection-inducing methods and compositions |
| 02/23/1995 | WO1995005183A1 Antimicrobial barrier composition |
| 02/23/1995 | WO1995005180A1 Methods and compositions for inhibiting uridine secretion |
| 02/23/1995 | WO1995005172A1 Methods for modulating the human sexual response |
| 02/23/1995 | WO1995005167A2 Treatment of adverse effects associated with administration of extracellular hemoglobin |
| 02/23/1995 | WO1995001420A3 A method of producing a protein disulfide redox agent |
| 02/23/1995 | DE3991484C2 Pharmaceutical composition containing a specific inhibitor of the enzymatic conversion of protoporphyrinogen to protoporphyrin IX by protoporphyrinogen oxidase |
| 02/23/1995 | CA2402590A1 Phospate-binding polymers for oral administration |
| 02/23/1995 | CA2169178A1 Composition and methods using nitroxides to avoid oxygen toxicity |
| 02/23/1995 | CA2167716A1 Treatment of adverse effects associated with administration of extracellular hemoglobin |
| 02/22/1995 | EP0639563A2 Use of cloprostenol, fluprostenol and their analogues for the manufacture of a medicament for the treatment of glaucoma and ocular hypertension |
| 02/22/1995 | EP0639373A1 Preparations for the external application of antiseptic agents and/or agents promoting the healing of wounds |
| 02/22/1995 | EP0639076A1 Use of guanylate cyclase inhibitors in the treatment of shock |
| 02/22/1995 | EP0639072A1 Pharmaceutical compositions of alkylsulphonamides 5ht1 agonists for rectal administration |
| 02/21/1995 | CA1334513C Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
| 02/16/1995 | WO1995004741A1 Aza-5,5-fused heterocyclic acids as leukotriene antagonists |
| 02/16/1995 | WO1995004531A1 Fibrinogen receptor antagonists |
| 02/16/1995 | WO1995004527A1 Gelatin capsules containing a highly concentrated acetaminophen solution |
| 02/16/1995 | CA2168668A1 Aza-5,5-fused heterocyclic acids as leukotriene antagonists |
| 02/16/1995 | CA2168581A1 Fibrinogen receptor antagonists |
| 02/16/1995 | CA2168566A1 Method and reagent for inhibiting human immunodeficiency virus replication |
| 02/15/1995 | EP0638317A1 Pharmaceutical composition |
| 02/15/1995 | EP0637964A1 Drugs for tumour therapy in conjunction control with and regulation of the immune system and use of the individual substances for combined therapy. |
| 02/15/1995 | EP0637946A1 Tissue-specific implantable therapeutic agent delivery system |
| 02/15/1995 | EP0637933A1 Method and kit for imaging and treating organs and tissues |
| 02/15/1995 | EP0425507B1 Compositions and methods for treating skin conditions and promoting wound healing |
| 02/14/1995 | US5389677 Method of treating wrinkles using glycalic acid |
| 02/14/1995 | US5389383 Method for treating hypoxia-associated ocular complications |
| 02/09/1995 | WO1995003804A1 Methods of enhancing opiate analgesic potency or detoxifying an opiate addict |
| 02/09/1995 | WO1994022437A3 Method for treating amyloidosis |